Congress hits panic button over potential Chinese heparin shortage as swine herds ravaged by disease     

A bipartisan group of U.S. Representatives have asked the FDA for assurance that the U.S. is not headed for a heparin shortage. (Image by JamesDeMers from Pixabay )

A decade ago, Congress was up in arms about Chinese crude heparin in the U.S. supply chain. Now members are highly concerned there may not be enough of it. 

Six congressional leaders from both parties are asking FDA Acting Commissioner Norman Sharpless to give them some assurances the U.S. heparin supply is not in danger of drying up as a result of African swine fever, which is wreaking havoc on pig herds in China, the primary source of crude heparin.

RELATED: Chinese heparin maker banned by EMA over contamination risks

Survey

Survey: The Critical Role of Innovation in Launching Successful OTC Products

This research aims to understand the importance of product innovation and dose forms in driving new product design and development, consumer engagement and purchase interest for Over-the-Counter medicines. The first 50 qualified respondents will receive a $5 Amazon gift card. Take the survey now.

"U.S. dependence on Chinese heparin and on one animal source raises risks of shortages," the representatives wrote in a letter to Sharpless. “Pharmaceutical researchers are raising concerns that the African swine fever outbreak in China 'has the potential to cause an unprecedented shortage of heparin’s raw material.'"

Crude heparin, which is used to manufacture the essential anticoagulant used in kidney dialysis and open heart surgeries, comes from pig intestines and China has reportedly already lost 150 million of its 440 million swine, the letter says. 

FDA rules require heparin be manufactured only from pig intestines, because when "ruminant" animals like cattle are used, there is a chance the raw material could be contaminated with bovine spongiform encephalopathy or oversulfated chondroitin sulfate (OSCS), a cheap filler that saves money but that can be deadly to patients. In 2008, Chinese heparin contaminated with OSCS was tied to the deaths of 80 dialysis patients in the U.S. As recently as last November, European regulators banned a Chinese supplier after finding contamination risks

The committee members pointed out that, since the disease was discovered in Chinese herds last year, the country has lost a reported 150 million hogs to the outbreak. While there is no immediate indication that China's hog herd problems are impacting the U.S. heparin levels, the letter points out that the current supply is already stressed. It has faced periodic shortages, like when a Baxter International plant was taken out of production by Hurricane Maria in 2017. 

RELATED: FDA asks that Baxter saline plants in Puerto Rico get power restored ahead of others

It was a decade ago that the FDA got whiplashed by Congressional leaders over tainted Chinese heparin in the U.S. supply. The investigation began after heparin batches were tied to hundreds of allergic reactions, some that proved fatal. The blood thinner had been tainted somewhere along the supply chain, which stretched into some mom-and-pop workshops in the Chinese countryside.

Suggested Articles

With drug-resistant bacteria on the rise, antibiotics have struggled to keep up. But with an FDA nod for Nabriva's Xenleta, some of that may change.

JAK drugs have run into safety issues, and if the label for AbbVie's Rinvoq is any indication, the FDA now believes those the issues are class-wide.

Rather than "we did the best we could," Vas Narasimhan, during an internal call with managers, said Novartis could have handled the Zolgensma crisis…